Colorectal Cancer - Spain Drug Forecasts and Treatment Analysis to 2020


#29459

152pages

GlobalData

$ 3000

In Stock


GlobalData, the industry analysis specialist, has released its new report, Colorectal Cancer Spain Drug Forecasts and Treatment Analysis to 2020. The report is an essential source of information and analysis on the Spanish colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the Spanish colorectal cancer therapeutics market. It analyses the treatment usage patterns in the Spanish colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the Spanish colorectal cancer therapeutics market, highlighting the opportunity for future players. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts. 

Scope

The scope of the report includes: 

  • An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized Spanish colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020. 
  • Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events. 
  • Competitor assessment including drug launch analysis and drug sales forecasts.
  • Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales forecast.
  • Analysis of unmet need in the market and target product profile including opportunity for target product. 
  • Technology trends analytic framework to assess strength of pipeline. 
  • Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
  • An overview of the most promising drugs including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
  • Analysis of the current and future market competition in the Spanish Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
  • Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
  • Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
  • Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in Spain.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop business strategies and perform superior market quantification analysis by 
  • Understanding the trends shaping and driving the Spanish colorectal cancer therapeutics market. 
  • Understanding treatment preferences of physicians in disease state and across treatment flow.
  • Accessing market sizing, forecasts and quantified growth opportunities in the Spanish colorectal cancer therapeutics market till 2020.
  • Quantifying patient population in Spain to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
  • Performing benchmarking analysis and growth opportunities against currently marketed products
  • Identifying market entry points based on safety, efficacy, and pricing parameters. 
  • Assessing competitiveness of products in market by understanding the strength and weakness of current competition. 
  • Develop and design your in-licensing and out-licensing strategies by 
  • Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
  • Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
  • Track drug sales in the Spanish colorectal cancer therapeutics market from 2001 to 2020
  • Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
  • Whats the next big thing in the Spanish Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize.
Table Of Content

1 Table of contents 3
1.1 List of Tables 6
1.2 List of Figures 6

2 Disease Overview 8
2.1 Overview 8
2.2 Epidemiology 9
2.3 Etiology 9
2.4 Symptoms 10
2.4.1 Colon Cancer 10
2.4.2 Rectal Cancer 10
2.5 Diagnosis 11
2.5.1 FOBT 11
2.5.2 Endoscopy 11
2.5.3 Optical Colonoscopy 12
2.5.4 Virtual Colonoscopy 12
2.5.5 Double Contrast Barium Enema (DCBE) 12
2.6 Pathology 12
2.6.1 Grading 13
2.7 Treatment 13
2.7.1 Colon Cancer Treatment by Stage 14
2.7.2 Rectal Cancer Treatment by Stage 16
2.7.3 Chemotherapy Options 19
2.8 Treatment Guidelines 21

3 Market Characterization 22
3.1 Spain 22
3.1.1 Market Size 22
3.1.2 Drivers and Barriers 27
3.1.3 Impact on the Market 29
3.1.4 Forecasts 30
3.1.5 Drug Sales 35
3.1.6 Pricing and Reimbursements 38
3.2 Key Takeaway 38

4 Competitor Assessment 39
4.1 Strategic Competitor Assessment 39
4.1.1 Overview 39
4.1.2 Benchmarking 39
4.1.3 Current Competitor Assessment 42
4.2 Launch Analysis and Sales Forecasts 42
4.2.1 Market Share Analysis of Drugs 42
4.3 Product Profiles 43
4.3.1 Avastin (bevacizumab) 44
4.3.2 Erbitux (cetuximab) 47
4.3.3 Xeloda (capecitabine) 52
4.3.4 Vectibix (panitumumab) 56
4.3.5 Eloxatin (oxaliplatin) 62
4.3.6 Camptosar (irinotecan) 66
4.3.7 Fluorouracil (5-FU) 68
4.3.8 Leucovorin (folinic acid) 69
4.4 Key Takeaway 70

5 Pipeline Assessment 71
5.1 Overview 71
5.2 Pipeline Analysis by Phase of Development 72
5.3 Pipeline by Mechanism of Action 73
5.4 Strategic Pipeline Assessment 74
5.4.1 Technology Trends Analytical Framework 74
5.5 Trends in Colorectal Cancer Pipeline 75
5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer 75
5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline 75
5.5.3 Failure of key Molecules in Phase II and Phase III Development 75
5.6 Partners in Development 76
5.6.1 Licensing Agreements by Phase of Development 76
5.6.2 Licensing Agreements by Geography 78
5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology 79
5.7 Most Promising Drugs Profiles 80
5.7.1 Aflibercept 80
5.7.2 Brivanib 82
5.7.3 OncoVAX 84
5.7.4 TroVax 86
5.7.5 KRX-0401 (Perifosine) 88
5.8 Colorectal Cancer Pipeline Preclinical Phase 90
5.9 Colorectal Cancer Pipeline Phase I 90
5.10 Colorectal Cancer Pipeline Phase II 92
5.11 Colorectal Cancer Pipeline Phase III 98
5.12 Key Takeaway 101

6 Unmet Need and Target Product Profile 102
6.1 Unmet Need 103
6.2 Opportunity for Target Product 104
6.3 Target Product Profile 105
6.3.1 Ideal Characteristics 105
6.3.2 Target Product Description 105
6.4 Key Takeaway 106

7 Strategic Assessment 107
7.1 Key Events Impacting the Future Market 107
7.2 Market Impact Analysis 107
7.3 Future Market Scenario 108
7.4 Key Takeaway 109

8 Company Profiles 110
8.1 F. Hoffmann La Roche 110
8.1.1 Business Description 110
8.1.2 Financial Overview 110
8.1.3 SWOT Analysis 110
8.2 Bristol-Myers Squibb 112
8.2.1 Business Description 112
8.2.2 Financial Overview 112
8.2.3 SWOT Analysis 113
8.3 Sanofi-Aventis 114
8.3.1 Business Description 114
8.3.2 Financial Overview 114
8.3.3 SWOT Analysis 114
8.4 Debiopharm Group 115
8.4.1 Business Description 115
8.5 Merck KGaA 115
8.5.1 Business Description 115
8.5.2 Financial Overview 116
8.5.3 SWOT Analysis 116
8.6 Regeneron 117
8.6.1 Business Description 117
8.6.2 Financial Overview 118
8.6.3 SWOT Analysis 118
8.7 Vaccinogen BD 119
8.7.1 Overview 119
8.7.2 SWOT Analysis 120
8.8 Oxford BioMedica 120
8.8.1 Business Description 120
8.8.2 Financial Overview 121
8.8.3 SWOT Analysis 122
8.9 Auron Healthcare GmbH 123
8.9.1 Company Overview 123
8.10 AEterna Zentaris 123
8.10.1 Business Description 123
8.10.2 Financial Overview 123
8.10.3 SWOT Analysis 124
8.11 Keryx 126
8.11.1 Business Description 126
8.11.2 Financial Overview 128
8.11.3 SWOT Anlaysis 128
8.12 Abbott Laboratories 130
8.12.1 Business Description 130
8.12.2 Financial Performance 131
8.12.3 SWOT Analysis 131
8.13 Pfizer 133
8.13.1 Business Description 133
8.13.2 Financial Overview 134
8.13.3 SWOT Analysis 134
8.14 Light Sciences Oncology, Inc 135
8.14.1 Business Description 135
8.14.2 Financial Overview 135
8.14.3 SWOT Analysis 135

9 Deals Analysis 138
9.1 Key Highlights 138
9.2 Key Deals Analysis 139
9.2.1 Eli Lilly Acquires ImClone 139
9.2.2 Astellas Pharma Acquires OSI Pharmaceuticals 139
9.2.3 Takeda Acquires IDM Pharma 139
9.2.4 Alchemia Acquires Meditech 139
9.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron 139
9.2.6 BBM Holdings to Acquire YM Biosciences 139
9.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis 139
9.2.8 Peptech Acquires cancer Antibodies from Scancell 140
9.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs 140
9.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc 140
9.3 Deals Analysis by Geography 140
9.4 Deals Analysis by Deal Size 141

10 Expert Opinion 142
10.1 Spain 142

11 Appendix 143
11.1 Market Definitions 143
11.2 Abbreviations 143
11.3 Research Methodology 145
11.3.1 Coverage 145
11.3.2 Secondary Research 145
11.3.3 Forecasting 146
11.3.4 Primary Research 149
11.3.5 Expert Panel validation 149
11.3.6 Contact Us 149
11.3.7 Disclaimer 149
11.3.8 Sources 150

Table 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010 9
Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010 13
Table 3: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 20012009 22
Table 4: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20012009 23
Table 5: Colorectal Cancer Therapeutics Market, Spain, Patient Volume (1000s), 20012009 24
Table 6: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20012009 25
Table 7: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 20092020 30
Table 8: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20092020 31
Table 9: Colorectal Cancer Therapeutics Market, Spain, Patient Volume (000), 20092020 32
Table 10: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20092020 33
Table 11: Colorectal Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2010 37
Table 12: Colorectal Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011-2020 37
Table 13: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010 41
Table 14: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010 43
Table 15: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010 45
Table 16: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010 48
Table 17: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010 53
Table 18: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010 57
Table 19: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010 58
Table 20: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010 63
Table 21: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010 63
Table 22: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010 79
Table 23: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010 90
Table 24: Colorectal Cancer, Global, Phase I Pipeline, July 2010 90
Table 25: Colorectal Cancer, Global, Phase II Pipeline, July 2010 92
Table 26: Colorectal Cancer, Global, Phase III Pipeline, July 2010 98
Table 27: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010 103
Table 28: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010 105
Table 29: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010 105
Figure 1: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010 21
Figure 2: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010 21
Figure 3: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 20012009 22
Figure 4: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20012009 23
Figure 5: Colorectal Cancer Therapeutics Market, Spain, Patient Volume, 20012009 24
Figure 6: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20012009 25
Figure 7: Colorectal Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009 27
Figure 8: Colorectal Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2010 29
Figure 9: Colorectal Cancer Therapeutics Market, Spain, Sales Value ($bn), 20092020 30
Figure 10: Colorectal Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 20092020 31
Figure 11: Colorectal Cancer Therapeutics Market, Spain, Patient Volume, 20092020 32
Figure 12: Colorectal Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 20092020 33
Figure 13: Colorectal Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 20092020 35
Figure 14: Colorectal Cancer Therapeutics Market, Spain, Drug Sales ($m), 2001-2020 36
Figure 15: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010 40
Figure 16: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010 42
Figure 17: Colorectal Cancer Therapeutics Market, Spain, Sales Forecast Split by Therapies, 2001-2020 43
Figure 18: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 20042010 46
Figure 19: Colorectal Cancer Therapeutics Market, Spain, Avastin, Sales Forecast ($m), 2005-2020 47
Figure 20: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 20042010 50
Figure 21: Colorectal Cancer Therapeutics Market, Spain, Erbitux, Sales Forecast ($m), 2004-2020 51
Figure 22: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010 52
Figure 23: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010 55
Figure 24: Colorectal Cancer Therapeutics Market, Spain, Xeloda, Sales Forecast ($m), 2001-2020 56
Figure 25: Colorectal Cancer Therapeutics Market, Global, Vectibix, Life Cyle Management Activities, 2010 60
Figure 26: Colorectal Cancer Therapeutics Market, Spain, Vectibix, Sales Forecast ($m), 2011-2020 61
Figure 27: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010 62
Figure 28: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Life Cyle Management Activities, 2010 64
Figure 29: Colorectal Cancer Therapeutics Market, Spain, Eloxatin, Sales Forecast ($m), 2001-2020 65
Figure 30: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure 66
Figure 31: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cyle Management Activities, 2010 67
Figure 32: Colorectal Cancer Therapeutics Market, Spain, Camptosar, Sales Forecast ($m), 2001-2020 68
Figure 33: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure 68
Figure 34: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure 69
Figure 35: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010 71
Figure 36: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010 72
Figure 37: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010 73
Figure 38: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010 74
Figure 39: Colorectal Cancer Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2010 75
Figure 40: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010 76
Figure 41: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010 78
Figure 42: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010 79
Figure 43: Colorectal Cancer Therapeutics Market, Spain, Aflibercept Sales Forecast ($m), 2011-2020 82
Figure 44: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010 82
Figure 45: Colorectal Cancer Therapeutics Market, Spain, Brivanib Sales Forecasts ($m), 2013-2020 84
Figure 46: Colorectal Cancer Therapeutics Market, Spain, OncoVAX Sales Forecast ($m), 2011-2020 86
Figure 47: Colorectal Cancer Therapeutics Market, Spain, TroVax Sales Forecast ($m), 2014-2020 88
Figure 48: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010 88
Figure 49: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010 102
Figure 50: Colorectal Cancer Therapeutics Market, Spain, Opportunity and Unmet Need, 2010 104
Figure 51: Colorectal Cancer, Global, Key Events Impacting the Future Market 107
Figure 52: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010 108
Figure 53: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010 138
Figure 54: Colorectal Cancer Therapeutics Market, Global, Merger and Acqusition Deals by Geography (%), 2010 140
Figure 55: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010 141
Figure 56: Colorectal Cancer Therapeutics Market, Spain, Key Data Inputs from Key Opinion Leader Interviews, July 2010 142
Figure 57: GlobalData Market Forecasting Model 148